News

Q&A: Two decades of research lead to treatment for rare, painful skin condition
Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now ...
New Skin Substitutes Offer Hope for Severe Burns
A dermal matrix - one of the latest advancements to regenerate skin after severe burns.Severe burns remain one of the most ...
Medical Dialogues10d
FDA Approves Zevaskyn for Treating RDEB-Related Blistering Wounds
The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering ...
Nature8d
FDA approves cell-sheet-based gene therapy for severe skin disease
“Grafting gene-corrected skin onto chronically open wounds of patients with recessive [DEB] promises the potential to provide long-term healing of wounds, reduction in pain and reduced risk of ...
US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.
Medscape16d
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
“Grafting gene-corrected skin onto chronically open wounds of patients with recessive dystrophic epidermolysis bullosa promises the potential to provide long-term healing of wounds, reduction in ...